Management will provide an update on recent clinical and regulatory developments regarding COVID-19 clinical trials, along with other strategic priorities:
1) BLA submissions to Health Canada, MHRA, EMA, and US FDA 2) HIV prevention trial/monotherapy trial 3) Potential revenue from HIV and manufacturing forecast 4) HIV Cure - amfAR 5) EUA submission timelines to same four agencies for COVID-19 6) Long-hauler clinical trial and potential data readout timelines 7) NASH trial and potential interim analysis timeline 8) Cancer trial Breakthrough Therapy designation potential timelines 9) GvHD trial status 10) Stroke/MS new trials in 2021 11) NASDAQ uplisting status